# SARS-CoV-2 IgG and IgM Serologic Assays

> **NCT04562246** · — · COMPLETED · sponsor: **Henry Ford Health System** · enrollment: 214 (actual)

## Conditions studied

- Covid19

## Interventions

- **DIAGNOSTIC_TEST:** Serologic assays for antibodies to SARS-CoV-2

## Key facts

- **NCT ID:** NCT04562246
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-14
- **Primary completion:** 2021-03-22
- **Final completion:** 2024-02-26
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562246, "SARS-CoV-2 IgG and IgM Serologic Assays". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04562246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*